Skip to main content
. Author manuscript; available in PMC: 2017 Jun 14.
Published in final edited form as: Circulation. 2016 Jun 14;133(24):2459–2502. doi: 10.1161/CIRCULATIONAHA.116.022194

Figure 4. Comparison of data from contemporary trials for aspirin in primary prevention of ASCVD in diabetes.

Figure 4

JPAD (Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes, n=2,539) and POPADAD (Prevention of Progression of Arterial Disease and Diabetes, n=1,276). Although there was a trend toward reduction in ischemic outcomes with aspirin therapy for primary prevention in diabetes in both trials (except for CHD or stroke death in POPADAD), there were very few events, highlighting an area of potential controversy in ASCVD risk reduction.